Oral Abstracts (Regular and Late-Breaking Submission)

O015/#502 Molecular stratification of ovarian clear cell carcinoma predicts clinical outcomes

Pub Date : 2022-12-01 DOI: 10.1136/ijgc-2022-igcs.17 S. Gordhandas, B. Manning-Geist, Anjelica Hodgson, Qin C Zhou, A. Iasonos, D. Chi, A. Momeni-Boroujeni, N. Abu-Rustum, Mario Leitão, K. L. Long Roche, Y. Sonoda, C. Aghajanian, K. Alektiar, R. Grisham, O. Zivanovic, L. Ellenson, B. Weigelt

O001/#504 Durvalumab, in combination with and following chemoradiotherapy, in locally advanced cervical cancer: results from the phase 3 international, randomized, double-blind, placebo-controlled calla trial

Pub Date : 2022-12-01 DOI: 10.1136/ijgc-2022-igcs.3 B. Monk, T. Toita, Xiaohua Wu, Juan Carlos Limón, Qi Zhou, R. Tarnawski, M. Mandai, R. Shapira-Frommer, U. Mahantshetty, Maria Del Pilar Estevez-Diz, Francisco Ramirez Godinez, S. Varga, Manuel Humberto Leiva Gálvez, Jung-Yun Lee, Y. Kreynina, Kathryn Howells, S. Wildsmith, H. Dry, A. Nunes, J. Mayadev

LB001/#1731 Late-breaking abstract presentation: overall survival by number of prior lines of chemotherapy in patients with BRCA-mutated platinum-sensitive relapsed ovarian cancer receiving olaparib treatment or non-platinum chemotherapy in SOLO3

Pub Date : 2022-12-01 DOI: 10.1136/ijgc-2022-igcs.1 Charles Leath Iii, G. Scambia, R. Villalobos, N. Colombo, D. Cibula, M. Bidziński, Jae-Weon Kim, J. Nam, R. Mądry, C. Hernández, P. Mora, S. Ryu, M. Ah-See, E. Lowe, N. Lukashchuk, Dave Carter, R. Penson